Eleven Biotherapeutics Inc. (EBIO) Shares Down 5.9%
Eleven Biotherapeutics Inc. (NASDAQ:EBIO)’s share price traded down 5.9% during trading on Wednesday . The company traded as low as $4.97 and last traded at $5.09, with a volume of 1,498,912 shares. The stock had previously closed at $5.41.
The company’s market cap is $71.52 million. The company has a 50-day moving average price of $3.36 and a 200-day moving average price of $1.50.
Eleven Biotherapeutics (NASDAQ:EBIO) last issued its quarterly earnings data on Friday, August 12th. The biopharmaceutical company reported ($0.33) EPS for the quarter. Equities research analysts forecast that Eleven Biotherapeutics Inc. will post ($1.75) earnings per share for the current year.
In other news, major shareholder Boxer Capital, Llc sold 1,042,000 shares of the business’s stock in a transaction that occurred on Monday, June 13th. The stock was sold at an average price of $2.74, for a total value of $2,855,080.00. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Eleven Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company through AMP-Rx, a protein engineering platform, is engaged in the discovery and development of protein therapeutics to treat diseases of the eye. The Company designs, engineers and generates a pipeline of protein therapeutic candidates that target cytokines, which are central to diseases of the eye.